Lysine
Amino acidsBiological Macromolecular ActivityMetabolic Activity AlterationUS-FDASourced from openFDA
GET
/api/v1/drug/lysineMechanism of action
Sourced from openFDAMechanism-of-action class: Biological Macromolecular Activity.
Indications
Sourced from openFDA- For the temporary relief of itchy, painful, red, or irritated skin, anxiousness, diarrhea, or indigestion.*
Dosage & administration
Sourced from openFDADIRECTIONS Place drops under tongue 30 minutes before/after meals. Adults and children 12 years and over: Take 10 drops up to 3 times per day. Consult a physician for use in children under 12 years of age.
Warnings & precautions
Sourced from openFDAIn case of overdose, get medical help or contact a poison control center right away. Keep out of the reach of children. If pregnant or breastfeeding, ask a healthcare professional before use.
Approval history
Sourced from openFDA- Jul 20, 1984NDANDA019018B Braun
- Aug 23, 1984NDANDA018931Baxter Hlthcare
- Sep 6, 1985NDANDA019398Otsuka Icu Medcl
- Oct 17, 1986NDANDA019492Otsuka Icu Medcl
- Dec 19, 1991NDANDA020041Otsuka Icu Medcl
- Dec 19, 1991NDANDA020015Otsuka Icu Medcl
- Mar 26, 1997NDANDA020678Baxter Hlthcare
- Sep 29, 1997NDANDA020734Baxter Hlthcare
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
2,199 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
Literature
Recent PubMed references pinned to Lysine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Fusion Arrest and Triggered Release of Contents in Coacervates via Oxidation-Assisted Interfacial Coating.Chembiochem : a European journal of chemical biology · 2026 · Jo SA, Pak M, Jeon HG, et al.PMID 42252774DOI 10.1002/cbic.70410
- CPT1B K321 crotonylation contributes to cardiac dysfunction in endotoxic shock.Experimental & molecular medicine · 2026 · Yang N, Yang J, Xu YF, et al.PMID 42209697DOI 10.1038/s12276-026-01730-2
- A Review of Approaches to the Synthesis of DCL-Based Prostate-Specific Membrane Antigen Ligands.International journal of molecular sciences · 2026 · Zyk NY, Butakova NS, Machulkin AE, et al.PMID 42196616DOI 10.3390/ijms27104642
- Construction of a Lysine Lactylation- and DNA Damage Repair-Related Gene Signature to Predict the Prognosis and Drug Sensitivity of Breast Cancer Patients.International journal of molecular sciences · 2026 · Zhu L, Yuan C, Li Y, et al.PMID 42196471DOI 10.3390/ijms27104493
- Kbhb Proteome Resource Reveals a Metabolic-Epigenetic Crosstalk Governing Rice Blast Resistance via OsACLA2 Activity Regulation.Journal of agricultural and food chemistry · 2026 · Fang Y, Li W, Zhou Y, et al.PMID 42186238DOI 10.1021/acs.jafc.6c01580
- Development of a Lysine-Reactive Targeted Covalent Inhibitor for the P300/CBP-Associated Factor Bromodomain Through Structure-Based Design.ChemMedChem · 2026 · Ede RR, Peterson KE, Begyinah RK, et al.PMID 42174376DOI 10.1002/cmdc.70301
- Cucurbit[n]uril (n = 6 and 7)-Based High Affinity Enrichment of Basic Peptides Containing Multiple K/R Residues via Supramolecular Affinity Chromatography.Analytical chemistry · 2026 · Tang R, Ma S, Bai Q, et al.PMID 42168806DOI 10.1021/acs.analchem.6c01762
- Sustainable EGCG:ε-Poly-l-lysine Polymer Dots: A Green Multifunctional Platform Integrating Potent Antibacterial Action and Cellular Imaging.Biomacromolecules · 2026 · Sahadevan R, Vijayan VN, Sadhukhan S, et al.PMID 42165447DOI 10.1021/acs.biomac.6c00384
Clinical trials
The 10 most recently updated of 276 ClinicalTrials.gov registrations naming Lysine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid CancerNot yet recruiting · Phase 1 · Phase 2 · Interventional · 18 enrolled · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT06991738updated 2026-06-12
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruiting · Phase 2 · Interventional · 70 enrolled · National Cancer Institute (NCI)NCT03606967updated 2026-06-12
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Active not recruiting · Phase 1 · Interventional · 31 enrolled · Novartis PharmaceuticalsNCT06379217updated 2026-06-10
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)Recruiting · Phase 2 · Interventional · 36 enrolled · The Methodist Hospital Research InstituteNCT05660083updated 2026-06-04
- Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in SpainRecruiting · Observational · 100 enrolled · Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT07624838updated 2026-06-03
- SMART Diets for MASLDRecruiting · Phase 2 · Interventional · 102 enrolled · Michigan State UniversityNCT07459504updated 2026-06-01
- Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical ProstatectomyActive not recruiting · Phase 3 · Interventional · 193 enrolled · Jonsson Comprehensive Cancer CenterNCT03582774updated 2026-05-26
- RYZ101 for the Treatment of Progressive or Recurrent Intracranial MeningiomaRecruiting · Phase 1 · Phase 2 · Interventional · 30 enrolled · Joshua PalmerNCT07150806updated 2026-05-22
- Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)Completed · Phase 3 · Interventional · 50 enrolled · University Hospital, BordeauxNCT02817789updated 2026-05-12
- Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in ChildrenRecruiting · Phase 3 · Interventional · 1,000 enrolled · Philip SpinellaNCT06070350updated 2026-05-11
Frequently asked questions
- How does Lysine work?
- Mechanism-of-action class: Biological Macromolecular Activity.
- What is Lysine used for?
- According to FDA labeling, Lysine carries indications including: For the temporary relief of itchy, painful, red, or irritated skin, anxiousness, diarrhea, or indigestion.*. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What class of drug is Lysine?
- Lysine is classified as Amino acids, Biological Macromolecular Activity, Metabolic Activity Alteration.
- What are the brand names for Lysine?
- Lysine is marketed under brand names including Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free.
Note. Data for
lysine is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.